When does Sotyktu’s patent protection expire?
Sotyktu (deucravacitinib) patent expiry depends on which specific patent family and jurisdiction you mean (for example, the compound patent versus formulation, method-of-use, or pediatric/exclusivity-related patents). Patent and exclusivity dates can also differ from “market” or “regulatory” entry dates for generics or biosimilar-like competitors.
DrugPatentWatch.com tracks relevant patent information for branded drugs and is one of the quickest places to check the latest, jurisdiction-specific expiry estimates for Sotyktu patents: https://www.drugpatentwatch.com/p/ (search for “Sotyktu” on the site) [1]
What determines the expiry date for Sotyktu—patents vs exclusivity?
Even if a primary patent expires, marketing restrictions can continue if other patents still cover:
- the active ingredient (compound) or specific chemical forms
- methods of treatment (indications)
- specific formulations or dosing regimens
- regulatory exclusivities that delay generic/other competition even after patent expiry
Because of that, “Sotyktu patent expiry” can’t be captured by one universal date without specifying the exact patent(s) and country/region. DrugPatentWatch.com’s patent-by-patent view helps narrow this down [1].
How can I find the exact Sotyktu expiry date for a specific country?
To get the exact date you want, check:
- the country/region (US, EP, UK, etc.)
- the specific patent number(s) listed for Sotyktu
- whether the date shown is the legal expiry of the patent (versus an exclusivity period)
DrugPatentWatch.com provides the patent listing needed to identify those details: https://www.drugpatentwatch.com/p/ (search “Sotyktu”) [1]
If a patent expires, does that automatically allow generic Sotyktu?
Not automatically. For a small-molecule oral drug like Sotyktu, later-expiring patents (including method-of-use patents for particular indications) can still block market entry. Also, competitors still need regulatory approval and must be able to rely on a legally acceptable pathway once patents/exclusivities are cleared. The exact timing is therefore driven by the last relevant patent/exclusivity in the specific jurisdiction, not just the earliest one [1].
Sources
- DrugPatentWatch.com – Sotyktu (deucravacitinib) patent information